## Mark D Lindner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6533185/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Implants of Encapsulated Human CNTF-Producing Fibroblasts Prevent Behavioral Deficits and Striatal Degeneration in a Rodent Model of Huntington's Disease. Journal of Neuroscience, 1996, 16, 5168-5181.	1.7	204
2	Reliability, Distribution, and Validity of Age-Related Cognitive Deficits in the Morris Water Maze. Neurobiology of Learning and Memory, 1997, 68, 203-220.	1.0	162
3	Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Experimental Neurology, 1995, 132, 62-76.	2.0	142
4	Long-Lasting Functional Disabilities in Middle-Aged Rats with Small Cerebral Infarcts. Journal of Neuroscience, 2003, 23, 10913-10922.	1.7	111
5	Dissociable Long-Term Cognitive Deficits after Frontal versus Sensorimotor Cortical Contusions. Journal of Neurotrauma, 1998, 15, 199-216.	1.7	109
6	An Assessment of the Effects of Serotonin 6 (5-HT6) Receptor Antagonists in Rodent Models of Learning. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 682-691.	1.3	98
7	Aging and atropine effects on spatial navigation in the Morris water task Behavioral Neuroscience, 1988, 102, 621-634.	0.6	96
8	Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behavioural Brain Research, 1999, 102, 1-16.	1.2	91
9	Blind rats are not profoundly impaired in the reference memory Morris water maze and cannot be clearly discriminated from rats with cognitive deficits in the cued platform task. Cognitive Brain Research, 1997, 5, 329-333.	3.3	80
10	Relationship between performance in the morris water task, visual acuity, and thermoregulatory function in aged F-344 rats. Behavioural Brain Research, 1991, 45, 45-55.	1.2	73
11	Short forms of the "reference-―and "working-memory―Morris water maze for assessing age-related deficits. Behavioral and Neural Biology, 1992, 58, 94-102.	2.3	72
12	Polymer-Encapsulated Genetically Modified Cells Continue to Secrete Human Nerve Growth Factor for over One Year in Rat Ventricles: Behavioral and Anatomical Consequences. Experimental Neurology, 1996, 140, 126-138.	2.0	72
13	Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease. Cell Transplantation, 1997, 6, 249-266.	1.2	68
14	Cellular Delivery of Human Cntf Prevents Motor and Cognitive Dysfunction in a Rodent Model of Huntington's Disease. Cell Transplantation, 1997, 6, 249-266.	1.2	67
15	Individual differences in the hotplate test and effects of habituation on sensitivity to morphine. Pain, 1996, 66, 265-270.	2.0	63
16	NIH peer review: Criterion scores completely account for racial disparities in overall impact scores. Science Advances, 2020, 6, eaaz4868.	4.7	63
17	Rescuing neurons from trans-synaptic degeneration after brain damage: Helpful, harmful, or neutral in recovery of function?. Canadian Journal of Psychology, 1990, 44, 276-292.	0.8	61
18	Rats with partial striatal dopamine depletions exhibit robust and long-lasting behavioral deficits in a simple fixed-ratio bar-pressing task. Behavioural Brain Research, 1997, 86, 25-40.	1.2	57

Mark D Lindner

#	Article	IF	CITATIONS
19	Scopolamine induced deficits in a battery of rat cognitive tests: comparisons of sensitivity and specificity. Behavioural Pharmacology, 2009, 20, 237-251.	0.8	57
20	Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping. Psychopharmacology, 2006, 188, 629-640.	1.5	55
21	The Pharmacology of DMP696 and DMP904, Non-Peptidergic CRF1 Receptor Antagonists. CNS Neuroscience & Therapeutics, 2006, 11, 21-52.	4.0	53
22	Clinical attrition due to biased preclinical assessments of potential efficacy. , 2007, 115, 148-175.		50
23	Pain-Related Disability and Effects of Chronic Morphine in the Adjuvant-Induced Arthritis Model of Chronic Pain. Physiology and Behavior, 1997, 62, 199-205.	1.0	46
24	Differential in Vivo Effects of Neurturin and Glial Cell-Line-Derived Neurotrophic Factor. Experimental Neurology, 1999, 160, 235-243.	2.0	45
25	Hypoxia produces cell death in the rat hippocampus in the presence of an A1 adenosine receptor antagonist: An anatomical and behavioral study. Neuroscience, 1992, 48, 807-812.	1.1	43
26	Validation of a rodent model of Parkinson's disease: Evidence of a therapeutic window for oral Sinemet. Brain Research Bulletin, 1996, 39, 367-372.	1.4	42
27	Scientific productivity: An exploratory study of metrics and incentives. PLoS ONE, 2018, 13, e0195321.	1.1	31
28	Therapeutic Potential of a Polymer-Encapsulated ?-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson's Disease. Cell Transplantation, 1998, 7, 165-174.	1.2	30
29	Chronic morphine reduces pain-related disability in a rodent model of chronic, inflammatory pain Experimental and Clinical Psychopharmacology, 1999, 7, 187-197.	1.3	26
30	Continued presence of intrastriatal but not intraventricular polymer-encapsulated PC12 cells is required for alleviation of behavioral deficits in Parkinsonian rodents. Cell Transplantation, 1996, 5, 589-596.	1.2	22
31	Did Experimenter Bias Conceal the Efficacy of Spinal Opioids in Previous Studies with the Spinal Nerve Ligation Model of Neuropathic Pain?. Anesthesiology, 2004, 100, 765-767.	1.3	22
32	Numerous adrenal chromaffin cell preparations fail to produce analgesic effects in the formalin test or in tests of acute pain even with nicotine stimulation. Pain, 2000, 88, 177-188.	2.0	20
33	Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed non-matching to position tests. Psychopharmacology, 2005, 178, 410-419.	1.5	20
34	Examining the Predictive Validity of NIH Peer Review Scores. PLoS ONE, 2015, 10, e0126938.	1.1	20
35	NIH Peer Review. American Journal of Evaluation, 2016, 37, 238-249.	0.6	20
36	Increased Levels of Truncated Nerve Growth Factor Receptor in Urine of Mildly Demented Patients With Alzheimer's Disease. Archives of Neurology, 1993, 50, 1054-1058.	4.9	19

Mark D Lindner

#	Article	IF	CITATIONS
37	Somatic Delivery of Catecholamines in the Striatum Attenuate Parkinsonian Symptoms and Widen the Therapeutic Window of Oral Sinemet in Rats. Experimental Neurology, 1997, 145, 130-140.	2.0	19
38	Soluble Aβ and cognitive function in aged F-344 rats and Tg2576 mice. Behavioural Brain Research, 2006, 173, 62-75.	1.2	17
39	Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy Experimental and Clinical Psychopharmacology, 2006, 14, 42-51.	1.3	16
40	An experimental test of the effects of redacting grant applicant identifiers on peer review outcomes. ELife, 2021, 10, .	2.8	16
41	Mammalian-Cell-Produced Neurturin (NTN) Is More Potent Than Purified Escherichia coli-Produced NTN. Experimental Neurology, 2000, 162, 189-193.	2.0	14
42	Intrathecal Polymer-Encapsulated Bovine Adrenal Chromaffin Cells Fail to Produce Analgesic Effects in the Hotplate and Formalin Test. Experimental Neurology, 2000, 165, 370-383.	2.0	14
43	Analgesic effects of adrenal chromaffin allografts: Contingent on special procedures or due to experimenter bias?. Journal of Pain, 2003, 4, 64-73.	0.7	14
44	No detectable analgesic effects in the formalin test even with one million bovine adrenal chromaffin cells. Pain, 2002, 99, 263-271.	2.0	12
45	Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease. , 2008, , 93-157.		10
46	Intraventricular encapsulated calf adrenal chromaffin cells: viable for at least 500 days in vivo without detectable adverse effects on behavioral/cognitive function or host immune sensitization in rats. Restorative Neurology and Neuroscience, 1997, 11, 21-35.	0.4	9
47	Effects of oral BMY 21502 on Morris water task performance in 16–18 month old F-344 rats. Psychopharmacology, 1992, 107, 485-488.	1.5	8
48	The analgesic potential of intraventricular polymer-encapsulated adrenal chromaffin cells in a rodent model of chronic neuropathic pain Experimental and Clinical Psychopharmacology, 2000, 8, 524-538.	1.3	8
49	Alleviation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts. Brain Research, 1996, 736, 99-110.	1.1	3
50	The analgesic potential of intraventricular polymer-encapsulated adrenal chromaffin cells in a rodent model of chronic neuropathic pain. Experimental and Clinical Psychopharmacology, 2000, 8, 524-38.	1.3	3
51	Development of Behavioral Outcome Measures for Preclinical Parkinson's Research. , 2000, , 153-169.		2
52	The partial-reinforcement extinction effect in 4–5-day-old guinea pigs. Learning and Behavior, 1983, 11, 337-340.	3.4	1
53	Conditional analgesia from spinally transplanted adrenal chromaffin cells. Pain, 2002, 95, 192-194.	2.0	0

#	Article	IF	CITATIONS
55	Treatment of Central Nervous System Diseases with Polymer-Encapsulated Xenogeneic Cells. , 1998, , 253-286.		0